# Intra-Cellular Therapies, Inc. clinical trials: 41 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials with Intra-Cellular Therapies, Inc. as lead sponsor, 12 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Intra-Cellular Therapies, Inc.: 41 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/intra-cellular-therapies-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 12
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 2, 2026 | NCT07856420 | A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an... | Intra-Cellular Therapies, Inc. | Phase 3 | Recruiting | Generalized Anxiety Disorder | 705 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856420) |
| September 8, 2026 | NCT07807865 | A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety... | Intra-Cellular Therapies, Inc. | Phase 3 | Recruiting | Generalized Anxiety Disorder | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807865) |
| August 5, 2026 | NCT07747389 | A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder | Intra-Cellular Therapies, Inc. | Phase 3 | Not yet recruiting | Depressive Disorder, Major | 585 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747389) |
| January 22, 2025 | NCT06786286 | A Mass Balance Study Following Subcutaneous Administration of \[14C\]-ITI-1284 to Healthy Male Subjects | Intra-Cellular Therapies, Inc. | Phase 1 | Completed | Healthy Volunteers | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06786286) |
| November 26, 2024 | NCT06706674 | Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | Intra-Cellular Therapies, Inc. | Phase 3 | Recruiting | Irritability Associated With Autism Spectrum Disorder | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06706674) |
| November 22, 2024 | NCT06701903 | Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | Intra-Cellular Therapies, Inc. | Phase 2 | Recruiting | Generalized Anxiety Disorder | 570 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06701903) |
| November 15, 2024 | NCT06690398 | Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients | Intra-Cellular Therapies, Inc. | Phase 3 | Recruiting | Irritability Associated With Autism Spectrum Disorder | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06690398) |
| October 21, 2024 | NCT06651567 | A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia | Intra-Cellular Therapies, Inc. | Phase 2 | Recruiting | Agitation Associated With Alzheimer's Dementia | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06651567) |
| October 4, 2024 | NCT06627413 | Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or... | Intra-Cellular Therapies, Inc. | Phase 1 | Completed | Schizophrenia or Schizoaffective | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06627413) |
| August 16, 2024 | NCT06557902 | Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder | Intra-Cellular Therapies, Inc. | Phase 1 | Completed | Autism Spectrum Disorder | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06557902) |
| August 6, 2024 | NCT06540833 | A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease | Intra-Cellular Therapies, Inc. | Phase 2 | Recruiting | Psychotic Disorders, Alzheimer Disease | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06540833) |
| June 28, 2024 | NCT06480383 | Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder | Intra-Cellular Therapies, Inc. | Phase 2 | Recruiting | Generalized Anxiety Disorder | 705 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06480383) |
| June 17, 2024 | NCT06462612 | Study of Lumateperone in the Treatment of Patients With Bipolar Mania | Intra-Cellular Therapies, Inc. | Phase 3 | Completed | Bipolar Disorder, Manic | 351 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06462612) |
| June 17, 2024 | NCT06462586 | Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania | Intra-Cellular Therapies, Inc. | Phase 3 | Completed | Bipolar Disorder, Manic | 354 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06462586) |
| April 18, 2024 | NCT06372964 | Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients | Intra-Cellular Therapies, Inc. | Phase 3 | Recruiting | Bipolar Depression | 384 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06372964) |
| March 7, 2024 | NCT06299410 | PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects | Intra-Cellular Therapies, Inc. | Phase 1 | Completed | Healthy Volunteers | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06299410) |
| January 29, 2024 | NCT06229210 | Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder | Intra-Cellular Therapies, Inc. | Phase 3 | Recruiting | Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06229210) |
| May 9, 2023 | NCT05850689 | Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Intra-Cellular Therapies, Inc. | Phase 3 | Recruiting | Major Depressive Disorder | 470 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05850689) |
| March 13, 2023 | NCT05766813 | Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease | Intra-Cellular Therapies, Inc. | Phase 2 | Completed | Parkinson Disease | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05766813) |
| February 16, 2023 | NCT05732194 | Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers | Intra-Cellular Therapies, Inc. | Phase 1 | Completed | Healthy Volunteers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05732194) |
| July 22, 2022 | NCT05470101 | A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects | Intra-Cellular Therapies, Inc. | Phase 1 | Completed | Healthy Volunteers | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05470101) |
| September 29, 2021 | NCT05061719 | An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Intra-Cellular Therapies, Inc. | Phase 3 | Completed | Major Depressive Disorder | 812 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05061719) |
| September 29, 2021 | NCT05061706 | Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Intra-Cellular Therapies, Inc. | Phase 3 | Completed | Major Depressive Disorder | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05061706) |
| August 2, 2021 | NCT04985942 | Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Intra-Cellular Therapies, Inc. | Phase 3 | Completed | Major Depressive Disorder | 485 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04985942) |
| July 12, 2021 | NCT04959032 | Lumateperone for the Prevention of Relapse in Patients With Schizophrenia | Intra-Cellular Therapies, Inc. | Phase 3 | Completed | Schizophrenia | 592 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04959032) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 3 |
| Phase 2 | 7 |
| Phase 3 | 21 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 28 |
| Recruiting | 11 |
| Not yet recruiting | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 9 |
| Bipolar Disorder | 8 |
| Depressive Disorder, Major | 6 |
| Generalized Anxiety Disorder | 4 |
| Autism Spectrum Disorder | 2 |
| Alzheimer Disease | 2 |
| Parkinson Disease | 2 |
| Heart Failure, Systolic | 1 |
| Dementia | 1 |
| Psychotic Disorders | 1 |
| Aberrant Motor Behavior in Dementia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Medical law firms in the United States](https://specstream.ai/data/businesses/medical-law-firms/united-states)
- [Rheumatology practices in the United States](https://specstream.ai/data/businesses/rheumatology-practices/united-states)
- [Woodworking supply stores in the United States](https://specstream.ai/data/businesses/woodworking-supply-stores/united-states)
- [Chemical plants in the United States](https://specstream.ai/data/businesses/chemical-plants/united-states)
- [Footwear wholesalers in the United States](https://specstream.ai/data/businesses/footwear-wholesalers/united-states)
- [Medical research institutes in the United States](https://specstream.ai/data/businesses/medical-research-institutes/united-states)
